Bibliography
- Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
- Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008;29(1):1-128. Available from: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
- Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2006;300:555-70
- de Muys J-M, Gourdeau H, Nguyen-Ba N, et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob Agents Chemother 1999;43:1835-44
- Taylor DL, Ahmed PS, Tyms AS, et al. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(±)- 2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antivir Chem Chemother 2000;11:291-301
- Bethell RC, Lie YS, Parkin NT. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir Chem Chemother 2005;16:295-302
- Gu Z, Allard B, de Muys JM, et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006;50:625-31
- Locas C, Ching S, Damment S. Safety profile of SPD754 in cynomolgus monkeys treated for 52 weeks. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, CA. Abstract 527
- Holdich T, Shiveley L, Sawyer J. Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers. Clin Drug Invest 2006;26:279-86
- Gu Z, Nguyen-Ba N, Ren C, et al. BCH-10618, a new heterosubstituted nucleoside analogue against HIV-1 infection [abstract]. Antivir Ther 2001;6(Suppl 1):8
- Cox S, Parkin N, Limoli K, Coates J. Antiviral activity of ATC in vitro against HIV isolates with combinations of NRTI resistance mutations. 11th European AIDS Conference, 24 – 27 October 2007, Madrid, Spain, abstract P7.1/02
- García-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77:5685-93
- Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the human immunodeficiency virus type sws1 reverse transcriptase inhibitor of abacavir (1592U89) after monotherapy and combination therapy. J Infect Dis 2000;181:912-20
- Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999;4:87-94
- Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997;41:757-62
- Frankel FA, Coutsinos D, Xu H, Wainberg MA. Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate. Antivir Chem Chemother 2007;18:93-101
- St Clair M, Martin J, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9
- Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 997;41:1094-8
- Nakatani-Freshwater T, Babayeva M, Dontabhaktuni A, Taft DR. Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and lamivudine in the isolated rat perfused kidney. J Pharmacol Exper Ther 2006;319:941-7
- Shiveley L, Struthers-Semple C, Cox S, Sawyer J. Pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers treated with trimethoprim-sulphamethoxazole. J Clin Pharm Ther 2008;33:45-54
- Sawyer J, Struthers-Semple C. Pharmacokinetics of apricitabine in healthy volunteers and HIV-infected individuals. XVI International AIDS Conference 2006, abstract TUPE0077
- Cahn P, Rolon M, Cassetti I, et al. Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Invest 2008;28:129-38
- Holdich T, Sawyer J. Influence of food on the pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor. Expert Opin Pharmacother 2008;9:2021-5
- Holdich T, Shiveley LA, Sawyer J. Effect of lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2007;51:2943-7
- Sawyer J, Cox S. In vitro pharmacology of Apricitabine, a new NRTI for HIV. XVI International AIDS Conference 2006, abstract CDB0046
- Ray AS. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev 2005;7:113-25
- Bethell R, de Muys J, Lippens J, et al. In vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob Agents Chemother 2007;51:2948-53
- Emtriva Product Information. Available from: www.gilead.com/pdf/emtriva_pi.pdf
- Moore SM, Linet O, Tackwell K, et al. Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir boosted tipranavir. 8th International Workshop on Clinical Pharmacology of HIV Therapy 2007, abstract 68
- Phillips L, Borin MT, Hopkins NK, Daenzer VL, Wang Y. The pharmacokinetics of nucleoside reverse transcriptase inhibitors when co-administered with the HIV protease inhibitor tipranavir in HIV-1 infected patients. 7th Conference on Retroviruses and Opportunistic Infections 2000, abstract 81
- Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Drug interactions of tipranavir, a new HIV protease inhibitor. Drug Metab Lett 2007;1:81-4
- Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59:550-8
- Cahn P, Cassetti I, Wood R, et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 2006;20:1261-8
- Cahn P, Altclas J, Martins M, et al. Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1 infected patients failing therapy with M184V and NRTI resistance. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2007, abstract WESS203
- Cahn P, Altclas J, Martins M, et al. 24 week data from study AVX-201: A prospective, randomised, double-blind, dose-ranging phase 2b study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. 15th Conference on Retroviruses and Opportunistic Infections 2008, abstract #793
- Cahn P, Altclas J, Martins M, et al. 48-week data from Study AVX-201 – a randomised phase 2b study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. 9th International Congress on Drug Therapy in HIV Infection, 9 – 13 November, 2008, Glasgow, UK, abstract 0414
- Oliveira M, Moisi D, Spira B, et al. Apricitabine (ATC) does not select additional drug resistance mutations in tissue culture in HIV-1 variants containing either K65R or M184V or M184V plus thymidine-associated mutations (TAMs). 11th European AIDS Conference 2007, abstract P7.1/01
- Cox S, Southby J, Moore S. Genotypic analysis of patients enrolled in Study AVX-201 and treated with apricitabine for 24 weeks. Antivir Ther 2008;13(Suppl 3):A22 [Abstract 20]
- Petrella M, Wainberg WA. Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev 2002;4:224-32
- Back N, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO Journal 1996;15:4040-9
- Miller MD, Margot NA, Hertogs K, et al. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001;20:1025-8
- de Baar MP, de Rooij ER, Smolders KGM, et al. Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells. Antivir Res 2007;76:68-74
- Cox S, Moore S, Southby J, Alsumde A. Safety profile of Apricitabine, a novel NRTI, during 24-week dosing in experienced HIV-1 infected patients. 17th International AIDS Conference 2008, abstract TUAB0106
- Moore SM, VanderLugt J, Tackwell K, et al. A thorough QT/QTc study in healthy volunteers of two doses of apricitabine compared to placebo and a moxifloxacin positive control. 8th International Workshop on Clinical Pharmacology of HIV Therapy 2007, abstract 29
- Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44
- Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004;170:229-38